Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Omega-3 fatty acids in the treatment of depression

a fatty acid and depression technology, applied in the field of psychiatric disorders, can solve the problems of no currently available antidepressant is acutely effective in more than 60-70% of patients, carries a substantial burden of side effects, sexual dysfunction, sleep disturbance, etc., and achieves the effects of reducing or eliminating symptoms, reducing frequency, and lessening the severity of depression

Inactive Publication Date: 2005-12-01
STOLL ANDREW
View PDF1 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The newer agents, such as the selective serotonin reuptake inhibitors (SSRIs), are far less toxic than the older classes of antidepressants, but even the SSRIs carry a substantial burden of side-effects, including sexual dysfunction, sleep disturbance, and weight gain (Kaplan, 1998).
In addition, no currently available antidepressant is acutely effective in more than 60-70% of the patients who receive it.
Furthermore, long-term data exists for only a few antidepressant drugs, and it appears that efficacy may diminish over time with some agents (Fredman S J, et al.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0006] In the following description, reference will be made to various methodologies well-known to those skilled in the art of medicine and pharmacology. Such methodologies are described in standard reference works setting forth the general principals of these disciplines. Included among the relevant references are: Goodwin, F. K. and Jamison, K. R., Manic Depressive Illness, Oxford University Press (1990); and Bloom, F. and Kupfer, D., Psychopharmacology. The Fourth Generation of Progress, Raven Press (1994).

[0007] A. Definitions

[0008] Major Depression: Major depression is characterized by two or more weeks of predominantly low mood or diminished interest in one's usual activities combined with four or more of the following symptoms: sleep alteration (either increased or decreased), inappropriate guilt or loss of self-esteem, altered appetite (either incresed or decreased), diminished energy, diminished concentration, psychomotor symptoms (either agitation or retardation), and su...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
timeaaaaaaaaaa
Statistical Manual of Mental Disordersaaaaaaaaaa
energyaaaaaaaaaa
Login to View More

Abstract

The present invention is directed to a method of treating patients with major depression by administering omega-3 fatty acids. These may be administered in a substantially purified form, as part of a pharmaceutical composition, or as part of a larger molecule, e.g., a triacylglycerol, which releases free fatty acid after ingestion by a patient. The present invention is also directed to triacylglycerols which are esterified at the gamma cardon of glycerol to phosphocholine and at either the alpha or beta carbon of glycerol to an omega-3 fatty acid. These “omega-3 phoshatidylcholines” are also used in the treatment of patients with major depression.

Description

[0001] This application is a continuation-in-part U.S. patent application entitled “Omega-3 Fatty Acids and Omega-3 Phosphatidylcholine in the Treatment of Bipolar Disorder”, filed Feb. 5, 2002, using Express Mail No.: ET796587916US, which is a continuation of U.S. Ser. No. 09 / 269,361, filed Mar. 22, 1999, now issued as U.S. Pat. No. 6,344,482, which claims priority from PCT / US97 / 06712, filed Apr. 23, 1997. The contents of all of these applications are incorporated herein by reference.FIELD OF THE INVENTION [0002] The present invention relates to medical treatments for psychiatric disorders. More specifically, it is concerned with novel methods and compositions for treating patients with unipolar major depression. BACKGROUND OF THE INVENTION [0003] Major depression is a neuropsychiatric illness characterized by a persistently low mood or diminished interests in one's surroundings, accompanied by at least several of the following symptoms: Reduced energy and motivation, difficulty co...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/00A61K31/202A61K31/5513A61K31/685A61K33/00A61K36/38A61K45/06A61P25/24C07F9/02
CPCA61K31/00A61K31/202A61K31/5513A61K31/685A61K33/00A61K45/06A61K2300/00A61P25/24
Inventor STOLL, ANDREW
Owner STOLL ANDREW
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com